Employing two different targeting approaches, genetic depletion and pharmacological inhibition using the DNMT3B selective inhibitor NA, we observed strong anti-myeloma effects, with a strong reduction in cell proliferation and clear induction of apoptosis. The gene discussed is DNMT3B; the disease is plasma cell myeloma.